Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session Item

Applications of photon and electron treatment planning
6032
Poster (digital)
Physics
Simplified models for radiotherapy-induced lung cancer risk evaluation in breast treatment
Alessia D'Anna, Italy
PO-1511

Abstract

Simplified models for radiotherapy-induced lung cancer risk evaluation in breast treatment
Authors:

Alessia D'Anna1, Giuseppe Stella1, Elisa Bonanno2, Giuseppina Borzì3, Nina Cavalli3, Andrea Girlando4, Anna Maria Gueli1, Martina Pace5, Lucia Zirone5, Carmelo Marino6

1University of Catania, Department of Physics and Astronomy "E. Majorana", Catania, Italy; 2Humanitas - Istituto Clinico Catanese, Department of Medical Physics, Misterbianco , Italy; 3Humanitas - Istituto Clinico Catanese, Department of Medical Physics, Misterbianco, Italy; 4Humanitas - Istituto Clinico Catanese, Department of Radiotherapy , Misterbianco, Italy; 5University of Catania, School of Medical Physics, Catania, Italy; 6Humanitas - Istituto Clinico Catanese, Department of Medical Physics, Catania, Italy

Show Affiliations
Purpose or Objective

Conserving surgery followed by external beam radiotherapy is considered the "Gold Standard" for early stage of breast cancer. This approach may introduce an excess risk for second cancer induction due to breast exposure to therapeutic doses. The aim of this study was to estimate radiotherapy-induced lung cancer risk and to propose simplified models useful in clinical routine to reduce it in a preventive way during the treatment planning phase.

Material and Methods

Using the Schneider Mechanistic Model, radiotherapy-induced lung cancer risk for breast cancer has been estimated for 288 patients (aged between 30 and 70 years) treated with Three-Dimensional Conformal Radiation Therapy and Standard Fractioned (3D-CRT SF) at Humanitas - Istituto Clinico Catanese (H-ICC) (Catania, Italy). Organ Equivalent Dose (OED), Excess Absolute Risk (EAR), Lifetime Attributable Risk (LAR) and Relative Risk (RR) values has been calculated implementing a Script (C# language) through the Varian Eclipse Scripting Application Programming Interface (ESAPI). Statistical parameters have been provided by several sources: H-ICC, Istituto Nazionale di Statistica (ISTAT) and Integrated Cancer Registry CT-ME-EN. Using a C++ code, simulations have been performed on the whole statistical sample imposing an attained patient’s age (agea) equal to 75 Y and an age of the patient during exposure (agee) varying between 30 and 70 years in steps of 5 years. In order to minimise the difference between LAR from Schneider model (LARSchneider) and LAR from simplified model a parameter optimisation process has been performed, i.e., a minimization of Mean Square Error (MSE). 

Results

The first step was to fit linearly LAR values as a function of OED for i-th agee (i = 30, 35, …70) (1), where ai is the i-th angular coefficient for the i-th ageehe next step was to relate the growth rate of the LAR to the time range agee-agea (fig.).The analytic relationship (R2=0.99) found was (1). Substituting (2) to (1) we obtained the simplified model named OSM (3). OSM optimised parameters obtained after optimisation process were: A=-0.340 [(1/10000 P) Gy-1], B=-11.688 [Y], C=144.557 [Gy-1]. The percentage differences (Δ%) between LARSchneider and LAROSM values were < 2%. A linear relation (R2=0.96) was found between OED and V4 (% lung volume absorbing a dose of 4 Gy) (4). Substituting (4) to (3) we obtained the simplified model named VSM (5). VSM optimised parameters obtained, after optimisation process were: A=-0.300 [(1/10000 P) Gy-1], B=-11.387 [Y], C=147.601 [Gy-1], M=0.830 [(1/10000 P) Gy-1], N =0.069 [Y]. The percentage differences (Δ%) between LARSchneider and LARVSM values were < 5%.

 


Conclusion

This study provided three different tools for risk calculation: Eclipse™ script, OSM and VSM. These, in different ways, allow the medical physicist to quickly obtain LAR values for each treatment plan, which is why they could easily be used in clinical practice.